Topical rapamycin in the treatment of facial angiofibromas in tuberous sclerosis: a systematic review based on evidence

Introduction facial angiofibromas of tuberous sclerosis are the most prevalent cutaneous manifestation, affecting 80% of patients, which cause facial lesions with negative psychosocial consequences. Newly, topical rapamycin has been established as an effective and safe therapy for this skin condition. Purpose to analyze the available scientific evidence about the effectiveness and safety of topical sirolimus in the treatment of facial angiofibromas in tuberous sclerosis. Methods a literature search was conducted in PubMed and Cochrane. Effectiveness and safety were analyzed along with the main characteristics of each formulation in all included studies. Results thirty studies were included involving a total of 508 patients, developed in the last 20 years. Four randomized clinical trial, 17 case series and 9 single case reports were founded. Multiple topical rapamycin concentrations (0.003-1%) and formulations (gel, ointment, solution) were found in literature. Rapamycin demonstrated its effectiveness in all studies included, except for 5 patients in a 1 b study. Rapamycin was shown to be safe for the treatment of FA. Conclusions Topical sirolimus can be considered an effective and safety option for the treatment of facial angiofibromas in tuberous sclerosis. However, further long-term studies need to establish an evidence-based therapeutic protocol. KEY MESSAGE Updated review to date in topical rapamycin for facial angiofibromas, allowing support in therapeutic decisions.

Automated summary

Topical sirolimus can be considered an effective and safe option for the treatment of facial angiofibromas in patients with tuberous sclerosis. Further long-term studies are needed to establish an evidence-based therapeutic protocol. Updated reviews on topical rapamycin for facial angiofibromas provide support for therapeutic decisions.